Lyell Immunopharma Advances CAR-T Candidate with Pivotal Head-to-Head Trial
Published on 09/19/2025 at 15:36 | Redaktion boerse-global.deLyell Immunopharma has initiated its crucial Phase 3 clinical trial, named PiNACLE – H2H, for its next-generation CAR T-cell therapy candidate, LYL314. This study represents a bold strategic move for the biotechnology firm, as it will directly compare LYL314 against approved CD19 CAR T-cell therapies in patients with aggressive large B-cell lymphoma.
The initiation of the PiNACLE – H2H study signals a direct competitive challenge from Lyell Immunopharma. The head-to-head trial design, pitting LYL314 against established CD19 CAR T-cell treatments, has a clear objective: to demonstrate either superior efficacy or an improved safety profile for second-line treatment of aggressive large B-cell lymphoma.
LYL314 is a novel, dual-targeting therapy designed to engage both CD19 and CD20 antigens. This next-generation... Read more...
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
